Evidence map›Paper›PMID 38903222›Full record

ReviewChemical science2024

The impact of earth-abundant metals as a replacement for Pd in cross coupling reactions.

Michael U Luescher, Fabrice Gallou, Bruce H Lipshutz

Abstract readReview
In one paragraph

Review in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael U LuescherChemical & Analytical Development, Novartis Pharma AG Postfach CH-4002 Basel Switzerland fabrice.gallou@novartis.com michael-1.luescher@novartis.com.ORCID https://orcid.org/0000-0002-3661-881X
Fabrice GallouChemical & Analytical Development, Novartis Pharma AG Postfach CH-4002 Basel Switzerland fabrice.gallou@novartis.com michael-1.luescher@novartis.com.ORCID https://orcid.org/0000-0001-8996-6079
Bruce H LipshutzDepartment of Chemistry & Biochemistry, University of California Santa Barbara CA 93106 USA lipshutz@chem.ucsb.edu.ORCID https://orcid.org/0000-0001-9116-7049

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Substitution of one metal catalyst for another is not as straightforward as simply justifying this change based on the availability and/or cost of the metals. Methodologies to properly assess options for reaction design, including multiple factors like a metal's availability, cost, or environmental indicators have not advanced at the pace needed, leaving decisions to be made along these lines more challenging. Isolated indicators can lead to conclusions being made in too hasty a fashion. Therefore, an extensive life cycle-like assessment was performed documenting that the commonly held view that methods using earth-abundant metals (and in this case study, Ni) are inherently green replacements for methods using palladium in cross-coupling reactions, and Suzuki-Miyaura couplings, in particular, is an incomplete analysis of the entire picture. This notion can be misleading, and unfortunately derives mainly from the standpoint of price, and to some degree, relative natural abundance associated with the impact of mining of each metal. A more accurate picture emerges when several additional reaction parameters involved in the compared couplings are considered. The analysis points to the major impact that use of organic solvents has in these couplings, while the metals themselves actually play subordinate roles in terms of CO

Identifiers

PMID38903222
PMCPMC11186335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.